Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...

Abemaciclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, in the same class as Pfizer's Ibrance (palbociclib) which was granted accelerated approval by the US FDA as a first-line therapy ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the ...

POETIC-A is investigating whether adding the drug abemaciclib alongside hormone therapy can help prevent higher risk early breast cancer from returning. Abemaciclib works by blocking molecules which ...

Tango Therapeutics (NASDAQ:TNGX) stock plunged 28% in morning trading Wednesday after the company announced updates on ...

CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...

Get detailed information on Abemaciclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

HR+ HER2-ve Breast Cancer Therapies- TQB3616 capsule, NTQ1062 with Fulvestrant, Pembrolizumab, Sacituzumab Govitecan, ...

On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be ...